The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
To read the full story
Related Article
- Penalty for Lengthy Drug Price Haggling – Interview 3: JMA Exec Suzuki Calls for Cooperation to Defend Universal Healthcare
March 3, 2014
- Penalty for Lengthy Drug Price Haggling – Interview 2: “Rule Could Ruin Trust with Wholesalers,” Says NPhA Chief Nakamura
February 25, 2014
- Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26%
February 12, 2014
REGULATORY
- MHLW Panel OKs Report on Clinical Trials, Calls for Model Project on FMV Cost Approach
June 13, 2025
- Latest Honebuto Draft Erases “Expansion” of CEA after LDP Pushback
June 12, 2025
- EquMet, Clenafin See Generic Entry in June Listing
June 12, 2025
- Ruling Bloc, Ishin Agree to Discuss Coverage of OTC-Like Drugs
June 12, 2025
- Include Repeal of Off-Year Drug Price Revision in Honebuto: DPP
June 12, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…